Email Article

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Jun 26, 2007 7:00 AM (959 days ago)SEATTLE, June 26Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced the publication of preclinical studies, which demonstrate that treatment with pixantrone (BBR 2778) resulted in minimal or no significant cardiotoxicity, while doxorubicin and mitoxantrone induced significant cardiac damage. The studies compared the cardiac side effects of equiactive doses of pixantrone to doxorubicin and mitoxantrone in mice pre-treated with a cardiotoxic dose of doxorubicin as well as in mice without prior treatment. The article was published in the June 2007 journal Investigational New Drugs.

http://www.examiner.com/p-4755~Publication_on_Pixantrone_Pre clinical_Studies_Demonstrates_Reduced_Cardiotoxicity_Compare d_to_Equiactive_Doses_of_Doxorubicin_and_Mitoxantrone.html

The above excerpt and link will be sent by email.

Your Email:

Friend's Email (separated by commas):

Message (optional):